Lepu Medical Technology (Beijing)

PW Medtech is an affiliate connected through founder Pu Zhongjie and his wife Zhang Yue'e, but it operates as a separate entity from the listed Lepu Medical parent. The precise ownership and governance separation between the two is not publicly detailed, reflecting the opaque holding structures common among Chinese family-linked industrial groups.

Lepu's corporate development strategy favors control positions and majority stakes, especially in assets that can be integrated into its device and pharmaceutical supply chains. However, the subsidiary listing of Lepu Biopharma in 2023 demonstrated a parallel willingness to use partial sell-downs as a financing and value-realization tool.

Lepu's mandate is tightly focused on cardiovascular health and adjacent medical technologies. The firm does not invest in consumer goods, general technology, real estate, or sectors outside the healthcare ecosystem, nor does it operate as a passive financial investor — its capital is deployed where it can exert operational influence.

Warburg Pincus was an early institutional backer between 2007 and 2013, assisting Lepu with balance-sheet restructuring and corporate governance upgrades ahead of the Shenzhen Stock Exchange listing in 2009. Its exit marked Lepu's transition from private growth-stage company to public-market entity, with capital deployment shifting to cash-flow and public-equity financing.